The UroVysion Option: All that’s required is a simple urine sample
UroVysion, a molecular test for bladder cancer, is an option to be discussed with your physician. You simply furnish a urine specimen, and your physician orders the molecular UroVysion test, which provides a positive or negative result, typically within 72 hours.
See UroVysion at a Glance
When You Receive Your Test Results...
The UroVysion test is particularly sensitive (100%) among the most severe tumors. This statistic is significant for women, in whom bladder cancer often is not detected until the later, Tis stage – cancer that is only in the innermost lining of the bladder and classed as "carcinoma in situ" (CIS or Tis). 1
If your UroVysion test is positive, you must see a urologist immediately for a workup that can determine the cancer’s stage and grade as well as the best treatment therapies. If UroVysion is negative, your physician should follow standard guidelines for managing intermittent hematuria and persistent hematuria; or, alternatively, refer you to a urologist for a cystoscopy (bladder scope), upper tract imaging, and/or other procedures, as recommended by the American Urological Association, in an effort to ascertain the causes of persistent or intermittent hematuria.
UroVysion is used as an aid (in conjunction with, and not in lieu of, standard diagnostic procedures) in the detection of bladder cancer in patients with hematuria.
PersonalizeDx is a CLIA-certified clinical laboratory that runs UroVysion, the only FDA-approved urine-based molecular test for the detection of bladder cancer. A FISH-based (fluorescence in situ hybridization) test, UroVysion uses four DNA probes. UroVysion is used in conjunction with and not in lieu of standard diagnostic procedures, as an aid in the initial diagnosis of bladder carcinoma in patients with hematuria and also in the subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer.
UroVysion Clinician Benefits
- Detects chromosomal abnormalities associated with the development and recurrence of bladder cancer.
- Delivers positive/negative results in suspicious cystoscopy or atypical cytology cases.
- Shows 100% sensitivity among the most severe tumors (T2 and Tis).
- Performs without interference in the presence of substances such as BCG, Mytomycin C, and Thiotepa in urine samples.
1. Halling KC, King W, Sokolova IA, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol, 2000; 164; 1768-1775.